Spots Global Cancer Trial Database for onc201
Every month we try and update this database with for onc201 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03492138 | Multiple Myelom... | ONC201 Ixazomib Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03492138 | Multiple Myelom... | ONC201 Ixazomib Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Study of ONC201 for Refractory Meningioma | NCT06012929 | Meningioma Refractory Meni... Relapsed Mening... | ONC201 | 19 Years - | University of Nebraska | |
| A Study of ONC201 for Refractory Meningioma | NCT06012929 | Meningioma Refractory Meni... Relapsed Mening... | ONC201 | 19 Years - | University of Nebraska | |
| Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas | NCT03134131 | Glioma | ONC201 | 3 Years - | Chimerix | |
| Combination Therapy for the Treatment of Diffuse Midline Gliomas | NCT05009992 | Diffuse Intrins... Diffuse Midline... Recurrent Diffu... Recurrent Diffu... Recurrent WHO G... WHO Grade III G... | ONC201 Radiation Thera... Paxalisib | 2 Years - 39 Years | University of California, San Francisco | |
| A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | NCT02038699 | Advanced Gliobl... Advanced Colore... Advanced Triple... Advanced Non-sm... | ONC201 | 18 Years - | Chimerix | |
| A Study of ONC201 for Refractory Meningioma | NCT06012929 | Meningioma Refractory Meni... Relapsed Mening... | ONC201 | 19 Years - | University of Nebraska | |
| ONC201 in Pediatric H3 K27M Gliomas | NCT03416530 | Diffuse Intrins... Glioma, Maligna... | ONC201 | 2 Years - 18 Years | Chimerix | |
| Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer | NCT03099499 | Endometrial Can... | ONC201 | 18 Years - | Fox Chase Cancer Center | |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | NCT05580562 | H3 K27M Glioma | ONC201 ONC201 + Placeb... Placebo | - | Chimerix | |
| Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas | NCT05392374 | Glioma | ONC201 | 6 Months - 18 Years | Chimerix | |
| Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03492138 | Multiple Myelom... | ONC201 Ixazomib Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | NCT05542407 | Endometrial Can... Metastasis | Atezolizumab ONC201 | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 | NCT05476939 | Diffuse Intrins... Diffuse Midline... | Everolimus ONC201 Radiotherapy | 6 Months - | Gustave Roussy, Cancer Campus, Grand Paris | |
| ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma | NCT03394027 | Triple Negative... Endometrial Can... Hormone Recepto... | ONC201 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| ONC201 in Adults With Recurrent H3 K27M-mutant Glioma | NCT03295396 | Glioma | ONC201 | 18 Years - | Chimerix | |
| ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer | NCT03485729 | Endometrial Can... | ONC201 | 18 Years - | Chimerix | |
| Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma | NCT02525692 | Glioblastoma Diffuse Midline... H3 K27M Glioma Thalamic Glioma Infratentorial ... Basal Ganglia G... | ONC201 | 16 Years - | Chimerix | |
| ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer | NCT03485729 | Endometrial Can... | ONC201 | 18 Years - | Chimerix | |
| ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer | NCT03485729 | Endometrial Can... | ONC201 | 18 Years - | Chimerix | |
| ONC201 in Adults With Recurrent H3 K27M-mutant Glioma | NCT03295396 | Glioma | ONC201 | 18 Years - | Chimerix | |
| Phase 2 Study of ONC201 in Neuroendocrine Tumors | NCT03034200 | Recurrent Neuro... Metastatic Neur... | ONC201 | 14 Years - | Case Comprehensive Cancer Center | |
| A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma | NCT04629209 | Glioblastoma | ONC201 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 | NCT05476939 | Diffuse Intrins... Diffuse Midline... | Everolimus ONC201 Radiotherapy | 6 Months - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer | NCT03099499 | Endometrial Can... | ONC201 | 18 Years - | Fox Chase Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
